Skip to Main Content

Paper Details

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Clin Lung Cancer
11
2021
Durvalumab, MYSTIC, Metastatic Non-Small-Cell Lung Cancer, NSCLC, PATIENTS, PD-L1, Patient, TC, Tremelimumab, appetite loss, durvalumab, dyspnea, fatigue, metastatic NSCLC, metastatic non-small-cell lung cancer, patient, patients, programmed cell death ligand 1, tremelimumab, tumor cell
Author NameAffiliation
Edward B GaronDavid Geffen School of Medicine, University of California/TRIO-US Network los angeles
Edward B GaronDavid Geffen School of Medicine, University of California/TRIO-US Network los angeles
Frances A ShepherdPrincess Margaret Cancer Centre and the Department of Medicine, University of Toronto
  • 1 - 3

Datasets

Release 1.2